Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor (POET-2)

Evaluation of the Diagnostic Accuracy and Safety of 123 I-ALTROPANE® as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes (POET-2)

This will be two separate but identical studies: ALSE-A-02a, ALSE-A02b. Each study is designed to evaluate the diagnostic accuracy and safety of a single dose of 123I-ALTROPANE® in subjects with upper extremity tremor for less than three years. Currently, no radiopharmaceutical diagnostic imaging agent has been approved by the FDA in the U.S. for use in diagnosing Parkinson disease and related Parkinsonian syndromes. The diagnosis of Parkinsonian syndromes in the U.S. is based on clinical criteria only. The goal is to demonstrate that 123I-ALTROPANE® paired with SPECT imaging permits a more accurate early diagnosis of Parkinson disease than a clinical diagnosis by a general neurologist.

Study Overview

• Status: Unknown
• Conditions: Parkinsonian Syndromes
• Intervention / Treatment: Drug: 123 I - ALTROPANE®

Detailed Description

Each study is a prospective, multi-center, non-randomized, open-label, out patient clinical trial which will include up to 240 subjects per study. Subjects will be male and female, age 40-80 years, with approximately 20 sites per study.

Subjects will participate in 5 study visits over the course of the study period. The screening visit will include an assessment of eligibility. The second visit will be the collection of the community neurologist's diagnostic assessment. The third visit, during which all subjects receive a single intravenous (IV) injection of 123I-ALTROPANE® and single photon emission computed tomography (SPECT) imaging, will include appropriate safety assessments before and after dosing. The fourth visit, to occur 24 to 72 hours after SPECT imaging, will include follow up safety assessments as well as the first Movement Disorder Specialist's (MDS) evaluation. The fifth visit, to occur 6 months (±7 days) after SPECT imaging, will include follow-up safety assessments as well as the MDS reevaluation and truth standard diagnosis. The subject's participation in the study will be up to 7 months.

• Study Type: Interventional
• Enrollment (Anticipated): 240
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Susan Flint, MS, RAC, CCRA, CCRP; Phone Number: 242 508-497-2360; Email: sflint@talarisadvisors.com

Study Locations

• United States
  • Massachusetts
    • Hopkinton, Massachusetts, United States, 01748
      • Alseres Pharmaceuticals, Inc
      • Contact: Susan Flint, MS, RAC, CCRA, CCRP; Phone Number: 242 508-497-2360; Email: sflint@talarisadvisors.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Subjects must provide written informed consent prior to the initiation of any study related procedures;
2. Age 40 to 80 years;
3. Subjects must have had upper extremity tremor for < 3 years duration.

Exclusion Criteria:

1. Any clinically significant acute or unstable physical or psychological illness based on medical history or physical examination at Visit 1, as determined by the PI;
2. Any unexpected clinically significant abnormal laboratory or electrocardiogram (ECG) results obtained at Visit 1 and as determined by the PI;
3. Any history or drug, narcotic, or alcohol abuse within 2 years before the date of informed consent, as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association, Fourth Edition, revised DSM-IVR, American Psychiatric Association, 1994;
4. Positive drug screen for opiates, cocaine or amphetamines at Visit 1;
5. Positive pregnancy test at Visit 1 and/or Visit 3;
6. Participation in an investigational drug or device clinical trial within 30 days prior to the date of informed consent;
7. Previous participation in any 123I-ALTROPANE® trial;
8. Any exposure to radiopharmaceuticals within 30 days prior to the date of informed consent;
9. Breast-feeding;
10. Inability to lie supine for 1 hour;
11. Any thyroid disease other than treated hypothyroidism;
12. Known sensitivity or allergy to iodine or iodine containing products;
13. Treatment within the 4 weeks before the date of the informed consent with buproprion, methylphenidate or amphetamine;
14. Any treatment with anti-Parkinson's drugs within 4 weeks before the date of informed consent.

Subject eligibility based on exclusion criteria 1, 2, 3, 4, and 20 will be confirmed at Visit 3 prior to dosing.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Parkinsonian Syndromes; Subjects with Parkinsonian Syndromes	Drug: 123 I - ALTROPANE®; 8.0 mCi (±1.0 mCi) will be administered intravenously to each subject.
Experimental: Non-Parkinsonian Syndromes; Subjects with Non-Parkinsonian Syndromes	Drug: 123 I - ALTROPANE®; 8.0 mCi (±1.0 mCi) will be administered intravenously to each subject.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
To evaluate the diagnostic accuracy of a single dose of 123 I-ALTROPANE® as an imaging agent to aid in the diagnosis of Parkinsonian syndromes (PS) in subjects with upper extremity tremor for less than 2 years.	7 months

Secondary Outcome Measures

Outcome Measure	Time Frame
To evaluate the safety of 123 I-ALTROPANE® in subjects with upper extremity tremor for less than 2 years.	7 months

Collaborators and Investigators

• Sponsor: Alseres Pharmaceuticals, Inc

Study record dates

Study Major Dates

• Study Start: July 1, 2010
• Primary Completion (Anticipated): July 1, 2011
• Study Completion (Anticipated): July 1, 2011

Study Registration Dates

• First Submitted: July 28, 2008
• First Submitted That Met QC Criteria: July 29, 2008
• First Posted (Estimate): July 30, 2008

Study Record Updates

• Last Update Posted (Estimate): February 3, 2010
• Last Update Submitted That Met QC Criteria: February 2, 2010
• Last Verified: February 1, 2010

More Information

Terms related to this study

• Keywords: Subjects; Diagnosis; Parkinson Disease; Essential Tremor; Tremor; Parkinsonian Tremor; Upper Extremity Tremor with duration of less than 2 years; Upper; Extremity; Less; Than 2 years
• Additional Relevant MeSH Terms: Pathologic Processes; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Disease; Basal Ganglia Diseases; Movement Disorders; Syndrome; Parkinsonian Disorders
• Other Study ID Numbers: ALSE-A-02a, ALSE-A-02b